PaulEliezerObersteinMD

Oncology • New York, NY

Gastrointestinal Cancer, Hematologic Oncology

Director, GI Medical Oncology. Assistant Director, Pancreatic Cancer Center. NYU Perlmutter Cancer Center

Join to view full profile

Dr. Oberstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Oberstein's full profile

Already have an account?

Office
240 East 38th Street
20th Floor
New York, NY 10016

Education & Training

Columbia University Mailman School of Public HealthMS, Biostatistics, 2013 - 2015
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2010 - 2013
Temple University HospitalResidency, Internal Medicine, 2006 - 2009
Ohio State University College of MedicineClass of 2006

Certifications & Licensure

NY State Medical License 2010 - 2025
PA State Medical License 2006 - 2010

Awards, Honors, & Recognition

Patient Oriented Research Scholarship Mailman School of Public Health, Columbia University, 2013-2015
Chief Fellow in Hematology/Oncology Columbia University Medical Center, 2012-2013

Clinical Trials

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting Start of enrollment: 2014 Feb 05
Completed
Phase 2
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Start of enrollment: 2014 Dec 16
Completed
Phase 3
A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma Start of enrollment: 2015 Mar 31
Completed
Phase 1, Phase 2
Collection and Storage of Tissue and Blood Samples From Patients With Cancer Start of enrollment: 2015 May 19
Recruiting
Perioperative Chemo and Pembrolizumab in Gastric Cancer Start of enrollment: 2017 Nov 25
Completed
Phase 2
Azacitidine and Pembrolizumab in Pancreatic Cancer Start of enrollment: 2017 Oct 01
Active, not recruiting
Phase 2
Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer Start of enrollment: 2022 Nov 15
Recruiting
Not Applicable
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study.
Joseph R Habib, Benedict Kinny-Köster, Ammar A Javed, Poitr Zelga, Lily V Saadat
Journal of Clinical Oncology. 2024-12-20
Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study.
Erkut H Borazanci, Nathan Bahary, Vincent Chung, Timothy K Huyck, Ebenezer A Kio
The Oncologist. 2024-11-04
3 citations
Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: ...
Philip A Philip, Vaibhav Sahai, Nathan Bahary, Amit Mahipal, Anup Kasi
Journal of Clinical Oncology. 2024-11-01

Press Mentions

Cancer Rates Rise Among People Under Age 50August 18th, 2023
Report Shows Alarming Rise in Colorectal Cancer Rates Among US Adults Under 55March 2nd, 2023
More Colon Cancer Cases Found in Younger People, New Report ShowsMarch 1st, 2023
Join now to see all

Grant Support

Pancreatic Cancer Action Network Translational Research GrantPancreatic Cancer Action Network2017–2019
KL2 Mentored Career Development AwardNIH2015–2017
Young Investigator AwardAmerican Society of Clinical Oncology2013–2014

Committees

Member, SWOG, GI Committee 2013 - Present
Member, Protocol Review and Monitoring Committee, Herbert Irving Comprehensive Cancer Center 2014 - 2018

Professional Memberships